DelveInsight has launched a new report on “Diffuse Large B-cell Lymphoma – Market Insights, Epidemiology, and Market Forecast-2030”.
DelveInsight’s ” Diffuse Large B-cell Lymphoma – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Diffuse Large B-cell Lymphoma, historical and forecasted epidemiology as well as the Diffuse Large B-cell Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts:
Request for Free Sample Report: https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-market
Scope of the Report:
Key Companies Covered:
Diffuse Large B-cell Lymphoma (DLBCL)is “a diffuse proliferation of large neoplastic B lymphoid cells with a nuclear size equal to or exceeding normal macrophage nuclei or more than twice the size of a normal lymphocyte.”
DLBCL is a heterogeneous entity that includes a number of different variants and subtypes, with the current interest in identifying additional prognostically meaningful subsets. It occurs in young adults around age 35 and it affects slightly more women than men.
Diffuse large B-cell lymphoma grows rapidly in the lymph nodes and frequently involves the spleen, liver, bone marrow or other organs. Usually, DLBCL development starts in lymph nodes in the neck or abdomen and is characterized by masses of large B cells.
The most common symptom is painless swelling in the neck, armpit or groin. Other symptoms may include:.
In 2016’s WHO updated classification, DLBCL is divided in to following entities, DLBCL, NOS (not otherwise specified); DLBCL subtypes (such as, T-cell/histiocyte-rich Large B-cell Lymphoma; Primary DLBCL of the central nervous system; Primary cutaneous DLBCL, leg type; EBV positive DLBCL, NOS) and Other lymphomas of large B-cells.
According to the Lymphoma Research Foundation, the occurrence of DLBCL generally increases with age, and most patients are over the age of 60 at diagnosis. It is more prevalent in male as compared to female.
Drugs Covered:
Table of Contents:
1. Key Insights
2. Executive Summary of Diffuse Large B-cell Lymphoma
3. Competitive Intelligence Analysis for Diffuse Large B-cell Lymphoma
4. Diffuse Large B-cell Lymphoma: Market Overview at a Glance
4.1. Diffuse Large B-cell Lymphoma Total Market Share (%) Distribution in 2017
4.2. Diffuse Large B-cell Lymphoma Total Market Share (%) Distribution in 2030
5. Diffuse Large B-cell Lymphoma: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Diffuse Large B-cell Lymphoma Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Diffuse Large B-cell Lymphoma Treatment and Management
8.2. Diffuse Large B-cell Lymphoma Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Diffuse Large B-cell Lymphoma Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
13. Diffuse Large B-cell Lymphoma: Seven Major Market Analysis
13.1. Key Findings
13.2. Diffuse Large B-cell Lymphoma Market Size in 7MM
13.3. Diffuse Large B-cell Lymphoma Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Diffuse Large B-cell Lymphoma Total Market Size in the United States
15.1.2. Diffuse Large B-cell Lymphoma Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Diffuse Large B-cell Lymphoma Total Market Size in Germany
15.3.2. Diffuse Large B-cell Lymphoma Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Diffuse Large B-cell Lymphoma Total Market Size in France
15.4.2. Diffuse Large B-cell Lymphoma Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Diffuse Large B-cell Lymphoma Total Market Size in Italy
15.5.2. Diffuse Large B-cell Lymphoma Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Diffuse Large B-cell Lymphoma Total Market Size in Spain
15.6.2. Diffuse Large B-cell Lymphoma Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Diffuse Large B-cell Lymphoma Total Market Size in the United Kingdom
15.7.2. Diffuse Large B-cell Lymphoma Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Diffuse Large B-cell Lymphoma Total Market Size in Japan
15.8.3. Diffuse Large B-cell Lymphoma Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Diffuse Large B-cell Lymphoma
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Request for Detailed TOC: https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-market
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-market